Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 322

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients?

Zoubek, A, Dockhorn-Dworniczak, B, Delattre, O, Christiansen, H, Niggli, F, Gatterer-Menz, I, Smith, T L, Jürgens, H, Gadner, H, Kovar, H · 1996 · Journal of Clinical Oncology

Abstract

PURPOSE: Because of the high heterogeneity of EWS gene fusions with FLI1 and ERG genes due to variable chromosomal breakpoint locations in Ewing tumors (ET) (14 different chimeric transcripts identified so far), we evaluated the clinical impact of the expression of diverse fusion transcripts in ET patients. PATIENTS AND METHODS: In a European multicenter study, 147 ET were analyzed by reverse-transcriptase polymerase chain reaction (RT-PCR) and the molecular data statistically compared with all clinical data available. RESULTS: Most tumors expressed chimeric transcripts with fusion of EWS exon 7 to FLI1 exon 6 (75 of 147) (type I) or five (39 of 147) and EWS exon 10 to FLI1 exon 5 (eight of 147) or 6 (five of 147). In five cases, chimerism between EWS exon 9 and FLI1 exons 4 and EWS exon 7 and FLI1 exon 7 or 8 was observed. Fifteen cases of EWS-ERG rearrangement were identified. In 85 of these patients treated in the European Cooperative Ewing Sarcoma Studies, molecular results were analyzed in comparison to age, sex, tumor localization, tumor volume, and disease extension. No significant correlation between the various fusion types and these features were observed. Relapse-free survival (RFS) for the 31 patients with localized disease and fusion type I tended to be longer compared with the 24 patients with localized tumors bearing other chimeric transcripts (P = .04). CONCLUSION: Results suggest a possible advantage in PFS for patients with localized disease and fusion type I transcripts, although this will require prospective validation with a larger number of patients and longer follow-up periods.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.1996.14.4.1245

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 322

Metadata

Authors
Zoubek, A., Dockhorn-Dworniczak, B., Delattre, O., Christiansen, H., Niggli, F., Gatterer-Menz, I., Smith, T. L., Jürgens, H., Gadner, H., & Kovar, H.
Venue
Journal of Clinical Oncology
Published
1996-04
Volume
14
Issue
4
Pages
1245-1251
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1892156002
Cited by
322
References
19
FWCI
19.06
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? https://app.cochat.ai/papers/10.1200/jco.1996.14.4.1245
The paper
Zoubek, A., Dockhorn-Dworniczak, B., Delattre, O., Christiansen, H., Niggli, F., Gatterer-Menz, I., Smith, T. L., Jürgens, H., Gadner, H., & Kovar, H. (1996). Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? Journal of Clinical Oncology. https://doi.org/10.1200/jco.1996.14.4.1245

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.